论文部分内容阅读
作者对48名6～12月龄的婴幼儿皮下接种了法国流感嗜血杆菌－破伤风类毒素结合疫苗（ACT－Hib），考察疫苗的安全性及免疫原性。全程接种2次，间隔1个月。接种剂量为10μg／0．5ml／人。接种后人体反应轻微，48人中仅1人（2．1％）有局部红晕，2人体温升至37．6和38．5℃，48h后全部恢复正常。免后1个月抗体水平明显提高，100％受试者抗体含量≥0．15μg／ml，GMT由免前的0.087μg／ml提高至18．56μg／ml。第2针免后1个月，80．9％的受试者抗体含量≥10μg／ml，GMT为22.52μg／ml。
Forty-eight infants and young children aged 6 to 12 months were vaccinated subcutaneously with ACT-Hib to determine the safety and immunogenicity of the vaccine. Inoculation 2 times, an interval of 1 month. Inoculation dose is 10 μg / 0.5 ml / person. After inoculation, there was a slight reaction in the human body. Only 1 out of 48 people (2.1%) had partial flush. The body temperature of 2 patients rose to 37.6 and 38.5 ℃, all returned to normal after 48h. After 1 month, the level of antibody increased significantly. The antibody level of 100% of the subjects was ≥ 0.15μg / ml and the GMT increased from 0.087μg / ml to 18.56μg / ml. One month after the second injection, 80.9% of the subjects had antibody levels ≥10μg / ml and GMT 22.52μg / ml.